Breast cancer screening for women ages 50 to 69 years a systematic review of observational evidence

Preventive Medicine

Volumn 53, Issue 3, 2011, Pages 108-114

  Harris, Russell ^a   Yeatts, John ^a   Kinsinger, Linda ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

Breast neoplasm; Early detection of cancer; Mass screening; Research design

Indexed keywords

ANTINEOPLASTIC AGENT; TAMOXIFEN;

BREAST CANCER; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; EARLY CANCER; EARLY DIAGNOSIS; GROUPS BY AGE; HUMAN; MEDLINE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW;

AGE FACTORS; AGED; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MIDDLE AGED; PREVENTIVE MEDICINE; RESEARCH DESIGN; RISK REDUCTION BEHAVIOR; TIME FACTORS; UNITED STATES; WOMEN'S HEALTH;

EID: 80052670271     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2011.07.004     Document Type: Review

References (33)

1. Anttila A., et al. Programme sensitivity and effectiveness of mammography service screening in Helsinki, Finland. J. Med. Screen. 2002, 9:153-158.
2. Ascunce E.N., et al. Changes in breast cancer mortality in Navarre (Spain) after introduction of a screening programme. J. Med. Screen. 2007, 14:14-20.
3. Berry D.A., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med. 2005, 353:1784-1792.
4. Booth C.M., Mackillop W.J. Translating new medical therapies into societal benefit. The role of population-based outcome studies. JAMA 2008, 300:2177-2179.
5. Broeders M.J.M., et al. Diverging breast cancer mortality rates in relation to screening? A comparison of Nijmegen to Arnhem and the Netherlands, 1969-1997. Int. J. Cancer 2001, 92:303-308.
6. Concato J., Horwitz R.I. Beyond randomised versus observational studies. Lancet 2004, 363:1660-1661.
7. Duffy S.W., et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trail and from the Breast Screening Programme in England. J. Med. Screen. 2010, 17:25-30.
8. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N. Engl. J. Med. 1988, 319:1681-1692. Early Breast Cancer Trialists' Collaborative Group.
9. Furlan A.D., et al. Methodological quality and homogeneity influenced agreement between randomized trials and nonrandomized studies of the same intervention for back pain. J. Clin. Epidemiol. 2008, 61:209-231.
10. Garne J.P., et al. Increasing incidence of and declining mortality from breast carcinoma. Trends in Malmö, Sweden, 1961-1992. Cancer 1997, 79:69-74.
11. Gorini G., et al. Breast cancer mortality trends in two areas of the province of Florence, Italy, where screening programmes started in the 1970s and 1990s. Br. J. Cancer 2004, 90:1780-1783.
12. Gotzsche P.C., Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst. Rev. 2011, Issue 1. Art. No.:CD001877. 10.1002/1465I858.CD001877.pub4.
13. Harris R. Effectiveness: the next question for breast cancer screening. J. Natl. Cancer Inst. 2005, 14:1021-1023.
14. Jonsson H., et al. Service screening with mammography of women aged 50-69years in Sweden: effects on mortality from breast cancer. J. Med. Screen. 2001, 8:152-160.
15. Jonsson H., et al. Service screening with mammography. Long-term effects on breast cancer mortality in the county of Gävlebord, Sweden. Breast 2003, 12:183-193.
16. Jonsson H., et al. Service screening with mammography in Northern Sweden: effects on breast cancer mortality - an update. J. Med. Screen. 2007, 14:87-93.
17. Jørgensen K.J., et al. Breast cancer mortality in organized mammography screening in Denmark: comparative study. BMJ 2010, 340:c1241.
18. MacMahon S., Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001, 357:455-462.
19. Nelson H.D., et al. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2009, 151:727-737.
20. Olsen A.H., et al. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. BMJ 2005, 10.1136/bmj.38313.639236.82.
21. Olsen A.H., et al. Estimating the benefits of mammography screening. The impact of study design. Epidemiology 2007, 18:487-492.
22. Otto S.J., et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 2003, 361:1411-1417.
23. Parvinen I., et al. Service screening mammography reduces breast cancer mortality among elderly women in Turku. J. Med. Screen. 2006, 13:34-40.
24. Sarkeala T., et al. Organised mammography screening reduced breast cancer mortality: a cohort study from Finland. Int. J. Cancer 2008, 122:614-619.
25. Schopper D., de Wolf C. How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur. J. Cancer 2009, 45:1916-1923.
26. The Swedish Organised Service Screening Evaluation Group Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol. Biomarkers Prev. 2006, 15:45-51.
27. Tabar L., et al. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003, 361:1405-1410.
28. Törnberg S., et al. Breast cancer incidence and mortality in the Nordic capitals, 1970-1998. Trends related to mammography screening programmes. Acta Oncol. 2006, 45:528-535.
29. U.S. Preventive Services Task Force Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2009, 151:716-726.
30. Vandenbroucke J.P. When are observational studies as credible as randomised trials?. Lancet 2004, 363:1728-1731.
31. Vijan S., et al. Are randomized controlled trials sufficient evidence to guide clinical practice in Type II (non-insulin-dependent) diabetes mellitus?. Diabetologia 2000, 43:125-130.
32. Von Elm E., et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann. Intern. Med. 2007, 147:573-577.
33. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333. Writing Group for the Women's Health Initiative Investigators.